Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 16/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.57 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.48 |
| ▸ | APP | P05067 | 7/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6891149 | 0.90 | BACE1 (0.58) | BACE1KCNH2BACE2APP | |
| SCHEMBL931798 | 0.90 | BACE1 (0.58) | BACE1KCNH2BACE2APPIDO1 | |
| SCHEMBL931611 | 0.74 | BACE1 (0.68) | BACE1KCNH2BACE2 | |
| SCHEMBL932165 | 0.73 | BACE1 (0.79) | BACE1KCNH2BACE2APPCTSD | |
| SCHEMBL932038 | 0.71 | BACE1 (1.00) | BACE1KCNH2BACE2APPCTSD | |
| SCHEMBL1025970 | 0.68 | BACE1 (0.53) | BACE1KCNH2BACE2APP | |
| SCHEMBL932205 | 0.68 | BACE1 (0.61) | BACE1KCNH2BACE2APP | |
| SCHEMBL932487 | 0.67 | BACE1 (0.60) | BACE1BACE2APP | |
| SCHEMBL21795013 | 0.66 | MAPT (0.44) | KCNH2EPHX2IDO1 | |
| SCHEMBL931589 | 0.66 | BACE1 (0.40) | BACE1KCNH2BACE2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011002408-A1 | NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011002408-A1 | NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |